Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

M. Alsina; A. Varga; A. Amatu; J. H.M. Schellens; P. O. Witteveen; V. Boni; V. Moreno; K. Bol; A. Lourbakos; M. Magin Ferrer; E. Wasserman

doi:10.1093/annonc/mdy282.048

Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

M. Alsina, A. Varga, A. Amatu, J. H.M. Schellens, P. O. Witteveen, V. Boni, V. Moreno, K. Bol, A. Lourbakos, M. Magin Ferrer, E. Wasserman

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	viii223-viii224
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy282.048
Publication status	Published - 1 Oct 2018

Access to Document

10.1093/annonc/mdy282.048

Cite this

Alsina, M., Varga, A., Amatu, A., Schellens, J. H. M., Witteveen, P. O., Boni, V., Moreno, V., Bol, K., Lourbakos, A., Magin Ferrer, M., & Wasserman, E. (2018). Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii223-viii224. https://doi.org/10.1093/annonc/mdy282.048

Alsina, M. ; Varga, A. ; Amatu, A. et al. / Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway : Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ). In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii223-viii224.

@article{19203b2331c64ce08ae20707becb4c00,

title = "Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)",

author = "M. Alsina and A. Varga and A. Amatu and Schellens, {J. H.M.} and Witteveen, {P. O.} and V. Boni and V. Moreno and K. Bol and A. Lourbakos and {Magin Ferrer}, M. and E. Wasserman",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy282.048",

language = "English",

volume = "29",

pages = "viii223--viii224",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Alsina, M, Varga, A, Amatu, A, Schellens, JHM, Witteveen, PO, Boni, V, Moreno, V, Bol, K, Lourbakos, A, Magin Ferrer, M & Wasserman, E 2018, 'Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii223-viii224. https://doi.org/10.1093/annonc/mdy282.048

Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ). / Alsina, M.; Varga, A.; Amatu, A. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii223-viii224.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway

T2 - Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

AU - Alsina, M.

AU - Varga, A.

AU - Amatu, A.

AU - Schellens, J. H.M.

AU - Witteveen, P. O.

AU - Boni, V.

AU - Moreno, V.

AU - Bol, K.

AU - Lourbakos, A.

AU - Magin Ferrer, M.

AU - Wasserman, E.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081531257&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy282.048

DO - 10.1093/annonc/mdy282.048

M3 - Article

C2 - 32136481

AN - SCOPUS:85081531257

SN - 0923-7534

VL - 29

SP - viii223-viii224

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Alsina M, Varga A, Amatu A, Schellens JHM, Witteveen PO, Boni V et al. Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii223-viii224. doi: 10.1093/annonc/mdy282.048

Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

Access to Document

Other files and links

Cite this